Therapy Areas: Oncology
Dizal's ZEGFROVY (sunvozertinib) receives accelerated FDA approval for non-small cell lung cancer treatment
3 July 2025 - Dizal (SSE:688192), a China-based biopharmaceutical company involved in developing novel medicines for the treatment of cancer and immunological diseases, announced on Wednesday that the...
RedHill Biopharma recruiting for expanded Phase 2 opaganib/darolutamide combination study in advanced prostate cancer
2 July 2025 - RedHill Biopharma Ltd (NASDAQ: RDHL), an Israeli specialty biopharmaceutical company, announced on Tuesday the initiation of patient recruitment into the Phase 2 study evaluating the eff...
Genenta Science reports long-term survival signals in glioblastoma study as genitourinary trial advances
1 July 2025 -

Clinical stage immuno-oncology company Genenta Science SPA (NASDAQ: GNTA) on Tuesday announced long-term follow-up data from its gl...

Amgen's Phase 3 bemarituzumab plus chemotherapy clinical trial meets primary endpoint
1 July 2025 - US pharmaceutical company Amgen (NASDAQ:AMGN) announced on Monday that the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its p...
TuHURA Biosciences acquires Kineta
1 July 2025 - TuHURA Biosciences Inc (NASDAQ:HURA), a Phase 3 immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, announced on Monday the successful c...
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
1 July 2025 - Tyra Biosciences Inc (Nasdaq:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth ...